Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse

This study tests whether a combination of two drugs — azacitidine and chidamide — given after a stem cell transplant can prevent acute myeloid leukemia (AML) from coming back. **You may be eligible if...** - You are 18–60 years old with a diagnosis of AML (not a specific subtype called M3) - Your AML has poor genetic features, did not respond to initial treatment, relapsed, or developed from another blood condition - You have recently had a stem cell transplant - Your performance status is adequate (ECOG 0–3) - Your expected survival is at least 3 months - Your blood counts and liver function meet required thresholds **You may NOT be eligible if...** - You have the M3 subtype of AML (acute promyelocytic leukemia) - You have significant transplant-related complications above Grade 2 - Your liver, kidney, or blood counts are too low - Your expected survival is less than 3 months Talk to your doctor to see if this trial is right for you.